A Review of Current and Emerging Therapies for Advanced Hepatocellular Carcinoma.
Hepatocellular carcinoma remains a leading cause of cancer-related deaths worldwide. Liver disease including cirrhosis and viral hepatitis remains among the leading causes of hepatocellular carcinoma and despite increased screening, many patients are diagnosed in the advanced stages precluding them...
| Publicado en: | Current Oncology Vol. 29; no. 9; pp. 6445 - 6463 |
|---|---|
| Autores principales: | , , , , , , |
| Formato: | Journal Article |
| Publicado: |
MDPI
Sep2022
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=159330473&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 159330473 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 11980052 5EKK jtl: Current Oncology issn: 11980052 maglogo: N pubinfo: dt: Sep2022 vid: 29 iid: 9 pid: 97109 pub: MDPI artinfo: ui: 159330473 10.3390/curroncol29090507 159330473 ppf: 6445 ppct: 18 formats: fmt: – @attributes: type: T – @attributes: type: P tig: atl: A Review of Current and Emerging Therapies for Advanced Hepatocellular Carcinoma. aug: au: Singh, Angelica Zahid, Sofia Noginskiy, Ilya Pak, Timothy Usta, Soeb Barsoum, Marina Khan, Uqba affil: New York Presbyterian Brooklyn Methodist Hospital—Weill Cornell Medical College, Brooklyn, NY 11215, USA sug: ab: Hepatocellular carcinoma remains a leading cause of cancer-related deaths worldwide. Liver disease including cirrhosis and viral hepatitis remains among the leading causes of hepatocellular carcinoma and despite increased screening, many patients are diagnosed in the advanced stages precluding them from locoregional therapy. Therapeutic agents for advanced hepatocellular carcinoma were limited to Sorafenib for several years; however, with the emergence of molecular targeted therapies including tyrosine kinase inhibitors and vascular endothelial growth factor inhibitors, in addition to immunotherapies, the way hepatocellular carcinoma is treated has changed significantly. In this review, we summarize the key clinical trials that lead to the approval of these agents for systemic treatment of hepatocellular carcinoma and discuss the preferred sequence of treatment options as well as prospective studies for management of hepatocellular carcinoma. pubtype: Academic Journal doctype: Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|